FLT3 (ITD)-W51

FLT3 · Variant type: fusion · HGVS: p.L601_K602insREYEYDL · Fusion partner: W51 (ITD)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	100.0%	0.0%	88.97
2	Sunitinib	99.4%	0.6%	91.73
3	Brigatinib	99.1%	0.9%	82.96
4	Ponatinib	97.8%	2.2%	78.23
5	Pacritinib	97.3%	2.7%	88.64
6	Quizartinib	96.9%	3.1%	99.50
7	Fostamatinib	96.7%	3.3%	96.74
8	Fedratinib	96.4%	3.6%	96.21
9	Selpercatinib	96.2%	3.8%	96.72
10	Defactinib	96.0%	4.0%	92.68
11	Pralsetinib	95.9%	4.1%	93.43
12	Sorafenib	95.9%	4.1%	96.72
13	Nintedanib	93.4%	6.6%	90.23
14	Entrectinib	91.4%	8.6%	93.69
15	Avapritinib	91.0%	9.0%	97.73
16	Alectinib	89.8%	10.2%	95.49
17	Cabozantinib	88.0%	12.1%	92.73
18	Canertinib	87.4%	12.6%	96.49
19	Erlotinib	77.1%	22.9%	99.75
20	Vandetanib	72.3%	27.7%	95.74
21	Rabusertib	71.4%	28.6%	98.74
22	Tenalisib	68.7%	31.3%	97.98
23	Ibrutinib	67.0%	33.0%	94.74
24	Osimertinib	62.6%	37.4%	97.24
25	Alpelisib	61.9%	38.1%	97.22

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	100.0%	99.2%	+0.8%
Sunitinib	99.4%	98.7%	+0.7%
Brigatinib	99.1%	98.1%	+1.0%
Ponatinib	97.8%	97.9%	-0.1%
Pacritinib	97.3%	93.6%	+3.7%
Quizartinib	96.9%	97.9%	-1.0%
Fostamatinib	96.7%	97.2%	-0.5%
Fedratinib	96.4%	98.2%	-1.8%
Selpercatinib	96.2%	96.1%	+0.0%
Defactinib	96.0%	94.6%	+1.5%
Pralsetinib	95.9%	97.6%	-1.7%
Sorafenib	95.9%	97.3%	-1.4%
Nintedanib	93.4%	95.2%	-1.8%
Entrectinib	91.4%	96.1%	-4.7%
Avapritinib	91.0%	88.6%	+2.4%
Alectinib	89.8%	84.5%	+5.3%
Cabozantinib	88.0%	95.0%	-7.1%
Canertinib	87.4%	86.3%	+1.1%
Erlotinib	77.1%	—	—
Vandetanib	72.3%	—	—
Rabusertib	71.4%	—	—
Tenalisib	68.7%	—	—
Ibrutinib	67.0%	88.1%	-21.1%
Osimertinib	62.6%	—	—
Alpelisib	61.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.5ms